The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Matthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, Maria Trojano, Alessandra Lugaresi, François Grand'Maison, Eva Havrdova, Dana Horakova, Cavit Boz, Celia Oreja-Guevara, Raed Alroughani, Gerardo Iuliano, Pierre Duquette, Marc Girard, Murat Terzi, Raymond Hupperts, Pierre Grammond, Thor Petersen, Ricardo Fernandez-Bolaños, Marcela FiolEugenio Pucci, Jeannette Lechner-Scott, Freek Verheul, Edgardo Cristiano, Vincent Van Pesch, Tatjana Petkovska-Boskova, Fraser Moore, Ilya Kister, Roberto Bergamaschi, Maria Laura Saladino, Mark Slee, Michael Barnett, Maria Pia Amato, Cameron Shaw, Neil Shuey, Carolyn Young, Orla Gray, Ludwig Kappos, Helmut Butzkueven, Tomas Kalincik, Vilija Jokubaitis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). Methods: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. Results: A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p

Original languageEnglish
Pages (from-to)520-532
Number of pages13
JournalMultiple Sclerosis Journal
Volume22
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Immunomodulation
Multiple Sclerosis
Mouth Diseases
Therapeutics
Survival Analysis
Observational Studies
Registries
Demography
Fingolimod Hydrochloride

Keywords

  • disease-modifying therapy
  • fingolimod
  • medication persistence
  • MSBase
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Warrender-Sparkes, M., Spelman, T., Izquierdo, G., Trojano, M., Lugaresi, A., Grand'Maison, F., ... Jokubaitis, V. (2016). The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 22(4), 520-532. https://doi.org/10.1177/1352458515594041

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. / Warrender-Sparkes, Matthew; Spelman, Tim; Izquierdo, Guillermo; Trojano, Maria; Lugaresi, Alessandra; Grand'Maison, François; Havrdova, Eva; Horakova, Dana; Boz, Cavit; Oreja-Guevara, Celia; Alroughani, Raed; Iuliano, Gerardo; Duquette, Pierre; Girard, Marc; Terzi, Murat; Hupperts, Raymond; Grammond, Pierre; Petersen, Thor; Fernandez-Bolaños, Ricardo; Fiol, Marcela; Pucci, Eugenio; Lechner-Scott, Jeannette; Verheul, Freek; Cristiano, Edgardo; Van Pesch, Vincent; Petkovska-Boskova, Tatjana; Moore, Fraser; Kister, Ilya; Bergamaschi, Roberto; Saladino, Maria Laura; Slee, Mark; Barnett, Michael; Amato, Maria Pia; Shaw, Cameron; Shuey, Neil; Young, Carolyn; Gray, Orla; Kappos, Ludwig; Butzkueven, Helmut; Kalincik, Tomas; Jokubaitis, Vilija.

In: Multiple Sclerosis Journal, Vol. 22, No. 4, 01.04.2016, p. 520-532.

Research output: Contribution to journalArticle

Warrender-Sparkes, M, Spelman, T, Izquierdo, G, Trojano, M, Lugaresi, A, Grand'Maison, F, Havrdova, E, Horakova, D, Boz, C, Oreja-Guevara, C, Alroughani, R, Iuliano, G, Duquette, P, Girard, M, Terzi, M, Hupperts, R, Grammond, P, Petersen, T, Fernandez-Bolaños, R, Fiol, M, Pucci, E, Lechner-Scott, J, Verheul, F, Cristiano, E, Van Pesch, V, Petkovska-Boskova, T, Moore, F, Kister, I, Bergamaschi, R, Saladino, ML, Slee, M, Barnett, M, Amato, MP, Shaw, C, Shuey, N, Young, C, Gray, O, Kappos, L, Butzkueven, H, Kalincik, T & Jokubaitis, V 2016, 'The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis', Multiple Sclerosis Journal, vol. 22, no. 4, pp. 520-532. https://doi.org/10.1177/1352458515594041
Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand'Maison F et al. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal. 2016 Apr 1;22(4):520-532. https://doi.org/10.1177/1352458515594041
Warrender-Sparkes, Matthew ; Spelman, Tim ; Izquierdo, Guillermo ; Trojano, Maria ; Lugaresi, Alessandra ; Grand'Maison, François ; Havrdova, Eva ; Horakova, Dana ; Boz, Cavit ; Oreja-Guevara, Celia ; Alroughani, Raed ; Iuliano, Gerardo ; Duquette, Pierre ; Girard, Marc ; Terzi, Murat ; Hupperts, Raymond ; Grammond, Pierre ; Petersen, Thor ; Fernandez-Bolaños, Ricardo ; Fiol, Marcela ; Pucci, Eugenio ; Lechner-Scott, Jeannette ; Verheul, Freek ; Cristiano, Edgardo ; Van Pesch, Vincent ; Petkovska-Boskova, Tatjana ; Moore, Fraser ; Kister, Ilya ; Bergamaschi, Roberto ; Saladino, Maria Laura ; Slee, Mark ; Barnett, Michael ; Amato, Maria Pia ; Shaw, Cameron ; Shuey, Neil ; Young, Carolyn ; Gray, Orla ; Kappos, Ludwig ; Butzkueven, Helmut ; Kalincik, Tomas ; Jokubaitis, Vilija. / The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. In: Multiple Sclerosis Journal. 2016 ; Vol. 22, No. 4. pp. 520-532.
@article{b5a611b8cfa64a38808743a3e0d2f66b,
title = "The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis",
abstract = "Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). Methods: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. Results: A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p",
keywords = "disease-modifying therapy, fingolimod, medication persistence, MSBase, Multiple sclerosis",
author = "Matthew Warrender-Sparkes and Tim Spelman and Guillermo Izquierdo and Maria Trojano and Alessandra Lugaresi and Fran{\cc}ois Grand'Maison and Eva Havrdova and Dana Horakova and Cavit Boz and Celia Oreja-Guevara and Raed Alroughani and Gerardo Iuliano and Pierre Duquette and Marc Girard and Murat Terzi and Raymond Hupperts and Pierre Grammond and Thor Petersen and Ricardo Fernandez-Bola{\~n}os and Marcela Fiol and Eugenio Pucci and Jeannette Lechner-Scott and Freek Verheul and Edgardo Cristiano and {Van Pesch}, Vincent and Tatjana Petkovska-Boskova and Fraser Moore and Ilya Kister and Roberto Bergamaschi and Saladino, {Maria Laura} and Mark Slee and Michael Barnett and Amato, {Maria Pia} and Cameron Shaw and Neil Shuey and Carolyn Young and Orla Gray and Ludwig Kappos and Helmut Butzkueven and Tomas Kalincik and Vilija Jokubaitis",
year = "2016",
month = "4",
day = "1",
doi = "10.1177/1352458515594041",
language = "English",
volume = "22",
pages = "520--532",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

AU - Warrender-Sparkes, Matthew

AU - Spelman, Tim

AU - Izquierdo, Guillermo

AU - Trojano, Maria

AU - Lugaresi, Alessandra

AU - Grand'Maison, François

AU - Havrdova, Eva

AU - Horakova, Dana

AU - Boz, Cavit

AU - Oreja-Guevara, Celia

AU - Alroughani, Raed

AU - Iuliano, Gerardo

AU - Duquette, Pierre

AU - Girard, Marc

AU - Terzi, Murat

AU - Hupperts, Raymond

AU - Grammond, Pierre

AU - Petersen, Thor

AU - Fernandez-Bolaños, Ricardo

AU - Fiol, Marcela

AU - Pucci, Eugenio

AU - Lechner-Scott, Jeannette

AU - Verheul, Freek

AU - Cristiano, Edgardo

AU - Van Pesch, Vincent

AU - Petkovska-Boskova, Tatjana

AU - Moore, Fraser

AU - Kister, Ilya

AU - Bergamaschi, Roberto

AU - Saladino, Maria Laura

AU - Slee, Mark

AU - Barnett, Michael

AU - Amato, Maria Pia

AU - Shaw, Cameron

AU - Shuey, Neil

AU - Young, Carolyn

AU - Gray, Orla

AU - Kappos, Ludwig

AU - Butzkueven, Helmut

AU - Kalincik, Tomas

AU - Jokubaitis, Vilija

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). Methods: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. Results: A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p

AB - Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). Methods: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. Results: A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p

KW - disease-modifying therapy

KW - fingolimod

KW - medication persistence

KW - MSBase

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84962517754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962517754&partnerID=8YFLogxK

U2 - 10.1177/1352458515594041

DO - 10.1177/1352458515594041

M3 - Article

AN - SCOPUS:84962517754

VL - 22

SP - 520

EP - 532

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 4

ER -